4D Molecular Therapeutics (FDMT) Proxy filing summary

Executive summary

• Annual Meeting scheduled for June 17, 2026, to be held virtually for increased participation and cost savings.

• Record date for voting eligibility is April 20, 2026, with 52,274,735 shares outstanding.

• Stockholders will vote on director elections, auditor ratification, and executive compensation, with additional business as may arise.

• Proxy materials and annual report are available online, with options for electronic or paper delivery.

Voting matters and shareholder proposals

• Election of three Class III directors to serve until the 2029 annual meeting.

• Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory, non-binding vote on executive compensation (say-on-pay).

• Board recommends voting FOR all proposals.

• Procedures for submitting shareholder proposals and director nominations for the 2027 meeting are detailed, with deadlines and requirements.

Board of directors and corporate governance

• Board consists of eight directors divided into three staggered classes, with detailed biographies and qualifications provided.

• Majority of directors are independent per Nasdaq standards; only the CEO is not independent.

• Board committees include Audit, Compensation, Nominating and Corporate Governance, and Science and Technology, each with defined roles and independent membership.

• Corporate Governance Guidelines and Code of Business Conduct and Ethics are in place and available online.

• Board and committees met regularly in 2025, with high attendance.